Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAIKH A ALI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1629026273
CMS profile
27495
Location
TOMBALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,329.49

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,329.49 151

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAIKH A ALI

NPI 1629026273 · CMS profile ID 27495

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

TOMBALL, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAIKH A ALI, NPI 1629026273, CMS profile ID 27495. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SHAIKH A ALI, NPI 1629026273, CMS profile ID 27495. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SHAIKH A ALI, NPI 1629026273, CMS profile ID 27495, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1629026273?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $2,329.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $9.1408/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062169 CMS
PFIZER INC. $17.1608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832811873 CMS
Amgen Inc. $26.1508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781117 CMS
Amgen Inc. $16.9208/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781069 CMS
Lilly USA, LLC $21.6208/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818745987 CMS
AbbVie Inc. $13.8008/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852429 CMS
Horizon Therapeutics plc $7.7608/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062163 CMS
Amgen Inc. $20.5908/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781113 CMS
AbbVie Inc. $26.0808/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852425 CMS
E.R. Squibb & Sons, L.L.C. $14.6008/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783480235 CMS
Novartis Pharmaceuticals Corporation $14.2408/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583843 CMS
Hikma Pharmaceuticals USA $11.1908/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 808537513 CMS
UCB, Inc. $16.0808/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807380989 CMS
AbbVie Inc. $26.2408/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852421 CMS
PFIZER INC. $22.3908/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832762285 CMS
PFIZER INC. $15.4808/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832672627 CMS
Novartis Pharmaceuticals Corporation $17.0007/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583841 CMS
Amgen Inc. $6.9007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781109 CMS
Amgen Inc. $21.5907/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781105 CMS
Janssen Biotech, Inc. $22.1807/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788494819 CMS
AbbVie Inc. $20.1407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852417 CMS
Horizon Therapeutics plc $20.0007/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062159 CMS
AbbVie Inc. $22.3107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852413 CMS
Horizon Therapeutics plc $3.2707/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062155 CMS
UCB, Inc. $28.9407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807380283 CMS
E.R. Squibb & Sons, L.L.C. $0.9607/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783480223 CMS
E.R. Squibb & Sons, L.L.C. $17.1207/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783480227 CMS
AbbVie Inc. $12.0307/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852409 CMS
PFIZER INC. $15.7007/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832566353 CMS
Amgen Inc. $22.9806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781101 CMS
AbbVie Inc. $15.5606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852405 CMS
AbbVie Inc. $24.8206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852401 CMS
Novartis Pharmaceuticals Corporation $12.5406/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812583839 CMS
Amgen Inc. $21.5006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781097 CMS
UCB, Inc. $8.5706/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807371957 CMS
Ultragenyx Pharmaceutical Inc. $19.0306/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848960765 CMS
E.R. Squibb & Sons, L.L.C. $0.7806/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783480225 CMS
Horizon Therapeutics plc $13.1206/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062151 CMS
Janssen Biotech, Inc. $17.0606/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788494823 CMS
Horizon Therapeutics plc $18.6106/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062147 CMS
Amgen Inc. $27.3506/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781179 CMS
AbbVie Inc. $16.7905/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852397 CMS
E.R. Squibb & Sons, L.L.C. $3.5305/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783480209 CMS
Amgen Inc. $15.4405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781065 CMS
Horizon Therapeutics plc $2.6805/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062143 CMS
AbbVie Inc. $27.6005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793852393 CMS
Horizon Therapeutics plc $7.5205/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062133 CMS
Horizon Therapeutics plc $1.1305/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797062139 CMS
Alexion Pharmaceuticals, Inc. $13.7405/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783106017 CMS
Amgen Inc. $7.7305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825781093 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,036.23 194
PY2020 $2,876.50 129
PY2021 $2,329.49 151
PY2022 $2,627.25 138
PY2023 $3,426.78 179
PY2024 $2,972.70 146
PY2025 $3,185.25 153

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,584,084.94 193
PY2024 Recipient $1,371.82 2
PY2024 Principal investigator $1,088,589.73 275
PY2023 Principal investigator $1,653,967.95 541
PY2022 Recipient $841.00 1
PY2022 Principal investigator $2,050,954.63 800
PY2021 Principal investigator $1,279,190.25 369
PY2020 Recipient $392.30 1
PY2020 Principal investigator $1,096,690.27 222
PY2019 Recipient $160,754.47 10
PY2019 Principal investigator $1,069,054.76 105

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

193 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $4,618.90 12/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202532166
Principal investigator 1 ABBVIE INC. $3,601.66 12/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202532178
Principal investigator 1 ABBVIE INC. $1,615.00 12/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202532252
Principal investigator 1 ABBVIE INC. $67.06 12/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202532012
Principal investigator 1 ABBVIE INC. $366.27 12/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202532014
Principal investigator 1 ABBVIE INC. $1,690.00 12/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202532026
Principal investigator 1 ABBVIE INC. $97.50 12/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202532072
Principal investigator 1 ABBVIE INC. $179.13 12/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202531694
Principal investigator 1 ABBVIE INC. $185.29 12/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202531742
Principal investigator 1 Janssen Research & Development, LLC $446.00 12/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402676
Principal investigator 1 Janssen Research & Development, LLC $12,749.00 12/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402617
Principal investigator 1 ABBVIE INC. $1,027.00 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202526458
Principal investigator 1 ABBVIE INC. $39.99 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202526460
Principal investigator 1 ABBVIE INC. $26.00 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202526462
Principal investigator 1 ABBVIE INC. $2,684.00 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202527168
Principal investigator 1 ABBVIE INC. $812.50 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202527248
Principal investigator 1 ABBVIE INC. $38,277.20 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202527250
Principal investigator 1 ABBVIE INC. $31,344.69 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202527468
Principal investigator 1 ABBVIE INC. $228.84 12/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202529080
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $691.65 12/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431622
Principal investigator 1 ABBVIE INC. $36.81 11/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202525632
Principal investigator 1 ABBVIE INC. $780.00 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202525286
Principal investigator 1 ABBVIE INC. $22.01 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202525302
Principal investigator 1 ABBVIE INC. $130.00 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202525304
Principal investigator 1 ABBVIE INC. $173.73 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202525306
Principal investigator 1 ABBVIE INC. $78.00 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202525308
Principal investigator 1 ABBVIE INC. $39.02 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202525310
Principal investigator 1 ABBVIE INC. $25.00 11/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202525350
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $46,683.30 11/19/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431614
Principal investigator 1 ABBVIE INC. $1,463.02 11/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202524437
Principal investigator 1 Janssen Research & Development, LLC $172.00 11/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402506
Principal investigator 1 Janssen Research & Development, LLC $293.21 11/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402579
Principal investigator 1 Janssen Research & Development, LLC $1,109.00 11/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402597
Principal investigator 1 ABBVIE INC. $47.54 11/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202524135
Principal investigator 1 ABBVIE INC. $1,040.00 11/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202524175
Principal investigator 1 ABBVIE INC. $85.98 11/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202524263
Principal investigator 1 ABBVIE INC. $975.00 11/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202523643
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $461.10 11/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431638
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,197.94 11/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431636
Principal investigator 1 ABBVIE INC. $3,476.66 11/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202523341
Principal investigator 1 ABBVIE INC. $77.21 11/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202523379
Principal investigator 1 ABBVIE INC. $3,476.66 11/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202523381
Principal investigator 1 ABBVIE INC. $7.73 11/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202523453
Principal investigator 1 ABBVIE INC. $712.40 11/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202523455
Principal investigator 1 ABBVIE INC. $131.34 11/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202523489
Principal investigator 1 ABBVIE INC. $44,279.00 11/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202522145
Principal investigator 1 ABBVIE INC. $38,555.79 11/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202522771
Principal investigator 1 ABBVIE INC. $2,793.20 11/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202521001
Principal investigator 1 Janssen Research & Development, LLC $9,341.00 11/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402529
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $230.55 10/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431612
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $123.23 10/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431608
Principal investigator 1 ABBVIE INC. $207.00 10/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202517327
Principal investigator 1 ABBVIE INC. $269.10 10/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202517329
Principal investigator 1 ABBVIE INC. $57.00 10/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202517331
Principal investigator 1 ABBVIE INC. $93.00 10/16/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202517345
Principal investigator 1 ABBVIE INC. $260.00 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202517021
Principal investigator 1 ABBVIE INC. $65.49 10/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202517033
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $502.18 10/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431667
Principal investigator 1 Janssen Research & Development, LLC $651.00 10/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402537
Principal investigator 1 ABBVIE INC. $60,458.90 10/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202516107
Principal investigator 1 ABBVIE INC. $191.45 10/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516271
Principal investigator 1 ABBVIE INC. $36,585.34 10/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202516273
Principal investigator 1 Janssen Research & Development, LLC $17,448.00 10/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402543
Principal investigator 1 ABBVIE INC. $66.60 09/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202512220
Principal investigator 1 ABBVIE INC. $208.00 09/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202512222
Principal investigator 1 ABBVIE INC. $4,618.90 09/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202512244
Principal investigator 1 ABBVIE INC. $1,188.20 09/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202512246
Principal investigator 1 ABBVIE INC. $118.38 09/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202512248
Principal investigator 1 Janssen Research & Development, LLC $110.00 09/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402494
Principal investigator 1 Janssen Research & Development, LLC $2,420.00 09/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402658
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,534.57 09/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431632
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $581.40 09/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431688
Principal investigator 1 ABBVIE INC. $70.60 09/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202508666
Principal investigator 1 ABBVIE INC. $677.30 09/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202508772
Principal investigator 1 ABBVIE INC. $39,207.10 09/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202508774
Principal investigator 1 ABBVIE INC. $4,443.00 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202507277
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,195.54 09/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431658
Principal investigator 1 Janssen Research & Development, LLC $1,260.00 09/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402604
Principal investigator 1 Janssen Research & Development, LLC $10,816.00 08/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402558
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $176.23 08/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431610
Principal investigator 1 ABBVIE INC. $48.48 08/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202504993
Principal investigator 1 ABBVIE INC. $2,500.00 08/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202504999
Principal investigator 1 ABBVIE INC. $312.00 08/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202505001
Principal investigator 1 ABBVIE INC. $42.43 08/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202503703
Principal investigator 1 ABBVIE INC. $1,759.00 08/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501226
Principal investigator 1 ABBVIE INC. $2,524.55 08/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202501338
Principal investigator 1 Janssen Research & Development, LLC $515.00 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402564
Principal investigator 1 Janssen Research & Development, LLC $387.00 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402585
Principal investigator 1 Janssen Research & Development, LLC $525.00 08/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402623
Principal investigator 1 Janssen Research & Development, LLC $5,775.00 07/31/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402628
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $230.55 07/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431604
Principal investigator 1 Janssen Research & Development, LLC $1,302.00 07/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402548
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $500.00 07/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431640
Principal investigator 1 Janssen Research & Development, LLC $16,741.00 07/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402574
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,888.12 07/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431630
Principal investigator 1 ABBVIE INC. $12,600.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202494719
Principal investigator 1 ABBVIE INC. $17,900.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202494721
Principal investigator 1 ABBVIE INC. $282.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494723
Principal investigator 1 ABBVIE INC. $14,949.00 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202494849
Principal investigator 1 ABBVIE INC. $1,187.30 07/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202494851
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/30/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402652
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,538.64 06/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431606
Principal investigator 1 Janssen Research & Development, LLC $172.00 06/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402633
Principal investigator 1 ABBVIE INC. $150.00 06/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202491881
Principal investigator 1 ABBVIE INC. $4,176.90 06/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202491319
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,284.94 06/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431624
Principal investigator 1 ABBVIE INC. $93.00 06/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202490761
Principal investigator 1 Eli Lilly and Company $205,598.98 06/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187879875
Principal investigator 1 Amgen Inc. $4,677.84 06/06/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246640835
Principal investigator 1 ABBVIE INC. $987.60 06/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202489367
Principal investigator 1 ABBVIE INC. $24,524.00 06/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202489369
Principal investigator 1 Janssen Research & Development, LLC $2,290.00 06/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402513
Principal investigator 1 ABBVIE INC. $225.00 05/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202486899
Principal investigator 1 ABBVIE INC. $114.00 05/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202486901
Principal investigator 1 ABBVIE INC. $50.00 05/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202486915
Principal investigator 1 ABBVIE INC. $110.00 05/29/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202486917
Principal investigator 1 ABBVIE INC. $7,500.00 05/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202486213
Principal investigator 1 Amgen Inc. $16,973.25 05/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) No dispute reported 06/30/2026 1246640975
Principal investigator 1 ABBVIE INC. $2,863.50 05/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481629
Principal investigator 1 ABBVIE INC. $3,044.00 05/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481631
Principal investigator 1 Janssen Research & Development, LLC $1,706.00 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402639
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $271.63 04/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431646
Principal investigator 1 ABBVIE INC. $75.00 04/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202475592
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,795.14 04/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431628
Principal investigator 1 ABBVIE INC. $136.00 04/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202469221
Principal investigator 1 ABBVIE INC. $4,567.20 04/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202469225
Principal investigator 1 Amgen Inc. $41,087.17 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246640977
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,876.14 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431644
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $53.00 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431650
Principal investigator 1 Janssen Research & Development, LLC $2,113.00 03/31/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402553
Principal investigator 1 ABBVIE INC. $50.00 03/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202467125
Principal investigator 1 ABBVIE INC. $150.00 03/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202465709
Principal investigator 1 Eli Lilly and Company $4,645.27 03/25/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187882386
Principal investigator 1 Janssen Research & Development, LLC $19,500.00 03/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175402568
Principal investigator 1 ABBVIE INC. $500.90 03/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202463955
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,666.74 03/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431634
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $470.42 03/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431684
Principal investigator 1 ABBVIE INC. $75.00 03/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202463128
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $309.40 03/13/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431679
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,813.61 03/07/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431663
Principal investigator 1 ABBVIE INC. $9,487.35 03/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202456679
Principal investigator 1 ABBVIE INC. $11,256.00 03/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202456796
Principal investigator 1 ABBVIE INC. $2,221.52 03/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202458882
Principal investigator 1 ABBVIE INC. $75.00 03/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202455638
Principal investigator 1 Eli Lilly and Company $25,225.00 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878873
Principal investigator 1 Janssen Research & Development, LLC $1,420.00 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402518
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,000.00 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431602
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,970.81 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431616
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $123.23 03/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431626
Principal investigator 1 ABBVIE INC. $452.30 02/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202454000
Principal investigator 1 ABBVIE INC. $75.00 02/26/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202454004
Principal investigator 1 ABBVIE INC. $500.00 02/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202453637
Principal investigator 1 UCB SA $147,612.27 02/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659106
Principal investigator 1 ABBVIE INC. $750.00 02/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202452256
Principal investigator 1 ABBVIE INC. $1,917.00 02/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202452260
Principal investigator 1 Janssen Research & Development, LLC $300.00 02/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175402500
Principal investigator 1 Janssen Research & Development, LLC $750.00 02/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402523
Principal investigator 1 Janssen Research & Development, LLC $425.00 02/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402611
Principal investigator 1 Janssen Research & Development, LLC $3,737.00 02/17/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175402646
Principal investigator 1 ABBVIE INC. $1,920.00 02/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202451925
Principal investigator 1 ABBVIE INC. $198.60 02/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202451929
Principal investigator 1 Amgen Inc. $13,778.28 02/14/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity No dispute reported 06/30/2026 1246640837
Principal investigator 1 Janssen Research & Development, LLC $172.00 02/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402590
Principal investigator 1 ABBVIE INC. $3,200.00 02/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202450674
Principal investigator 1 Eli Lilly and Company $498.25 02/10/2025 Non-covered Recipient Entity
GCM MEDICAL GROUP PSC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883456
Principal investigator 1 ABBVIE INC. $2,500.00 02/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202448044
Principal investigator 1 ABBVIE INC. $1,920.00 02/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202448048
Principal investigator 1 ABBVIE INC. $750.00 02/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202448081
Principal investigator 1 ABBVIE INC. $16,000.00 02/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202448086
Principal investigator 1 Janssen Research & Development, LLC $727.00 02/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402664
Principal investigator 1 Janssen Research & Development, LLC $750.00 02/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175402681
Principal investigator 1 ABBVIE INC. $6,272.00 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202444747
Principal investigator 1 ABBVIE INC. $2,711.55 02/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444751
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,646.60 02/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431648
Principal investigator 1 Eli Lilly and Company $3,148.99 01/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187878877
Principal investigator 1 Janssen Research & Development, LLC $7,620.00 01/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175402671
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $17,828.94 01/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
INSPIRE LTE study No dispute reported 06/30/2026 1246431671
Principal investigator 1 Amgen Inc. $13,073.77 01/24/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS
DAZ-301 P3 DAZ Efficacy/Safety in Mod-Severe SS No dispute reported 06/30/2026 1246640839
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,516.00 01/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431654
Principal investigator 1 ABBVIE INC. $592.00 01/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202441035
Principal investigator 1 ABBVIE INC. $98.60 01/23/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202441038
Principal investigator 1 Eli Lilly and Company $24,884.00 01/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187879879
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,374.05 01/22/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431642
Principal investigator 1 Eli Lilly and Company $42,750.00 01/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878879
Principal investigator 1 ABBVIE INC. $2,615.00 01/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202438612
Principal investigator 1 ABBVIE INC. $625.00 01/15/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202438621
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,627.60 01/15/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190307907
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $192.60 01/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431675
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,374.00 01/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246431618
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,379.91 01/10/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431620
Principal investigator 1 Amgen Inc. $3,465.00 01/08/2025 Non-covered Recipient Entity
DM CLINICAL RESEARCH - MIGRAINE AND COPD - PPDS
DAZ-303 P3 DAZ Efficacy/Safety in SS w/ESSPRI >5 No dispute reported 06/30/2026 1246640841
Principal investigator 1 Eli Lilly and Company $233,145.14 01/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP, DBA DM CLINICAL RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883896
Principal investigator 1 Amgen Inc. $2,983.49 01/02/2025 Non-covered Recipient Entity
SOUND CLINICAL RESEARCH, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246648338